Abstract
Despite the youth of the chemokine field, many antagonists of chemokine function have already been identified and tested at the preclinical level. These include neutralizing antibodies, peptidyl and non-peptidyl antagonists and non-specific immunosuppressive agents. These early studies suggest that chemokine agonists have the potential to regulate many diseases, ranging from HIV-1 infection and tumor growth to acute and chronic inflammation. Clinical application will depend on pharmaceutical development. Great strides have been made in defining structural domains of the chemokines involved in receptor binding and activation. The identification of receptors is rapidly progressing, but with 50 potential ligands and 15 characterized receptors, it is obvious that additional molecular studies are needed. The intriguing observation that several pathogens either use chemokine receptors as entry portals or produce chemokine decoys to subvert the immune system suggests that there is much to be learned about the immune system from studies of “virokines.” Future studies should lead to the discovery and design of more effective inhibitors and antagonists with therapeutic benefit.
Article PDF
Similar content being viewed by others
REFERENCES
Baggiolini M: Chemokines and leukocyte traffic. Nature 392:565–568, 1998
Zlotnik A, Morales J, Hedrick JA: Recent advances in chemokines and chemokine receptors. Crit Rev Immunol 19:1–47, 1999
Rollins BJ: Chemokines. Blood 90:909–928, 1997
Howard OM, Ben-Baruch A, Oppenheim JJ: Chemokines: progress toward identifying molecular targets for therapeutic agents. Trends Biotechnol 14:46–51, 1996
Yang D, Chertov O, Bykovskaia S, et al.: Human beta-defensins promote adaptive immunity, by activating dendritic and T cells expressing CCR6. Science (in press)
Oppenheim JJ, Wang JM, Chertov O, et al.: The role of chemokines in transplantation. In Transplant Biology, NL Tilney, TB Storm, LC Paul (eds). Philadelphia, Lippincott-Raven, 1996, pp 187–220
Littman DR: Chemokine receptors: Keys to AIDS pathogenesis? Cell 93:677–680, 1998
Kledal TN, Rosenkilde MM, Coulin F, et al.: A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science 277:1656–1659, 1997
Lalani AS, McFadden G: Secreted poxvirus chemokine binding proteins. J Leukocyte Biol 62:570–566, 1997
Yang X-D, Corvalan JRS, Wang T, et al.: Fully human anti IL-8 monoclonal antibody: Potential therapeutics for the treatment of inflammatory disease states. J Leukocyte Biol 66:401–410, 1999
Harada A, Sekido N, Akahoshi T, et al.: Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukocyte Biol 56:559–564, 1994
Matsumoto T, Yokoi K, Mukaida N, et al.: Pivotal role of interleukin-8 in the acute respiratory distress syndrome and cerebral reperfusion injury. J Leukocyte Biol 62:581–587, 1997
Ono K, Matsumori A, Furukawa Y, et al.: Prevention of myocardial reperfusion injury in rats by an antibody against monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab Invest 79:195–203, 1999
Lloyd C, Gutierrez-Ramos JC: The role of chemokines in tissue inflammation and autoimmunity in renal diseases. Curr Opin Nephrol Hypertens 7:281–287, 1998
Arenberg DA, Kunkel SL, Polverini PJ, et al.: Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 97:2792–2802, 1996
Karpus WJ, Kennedy KJ: MIP-lalpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J Leukoc Biol 62:681–768, 1997
Greenberger MJ, Strieter RM, Kunkel SL, et al.: Neutralization of macrophage inflammatory protein-2 attenuates neutrophil recruitment and bacterial clearance in murine Klebsiella pneumonia. J Infect Dis 173:159–165, 1996
Moser B, Dewald B, Barella L, et al.: Interleukin-8 antagonists generated by N-terminal modification. J Biol Chem 268:7125–7158, 1993
Baly DL, Horuk R, Yansura DG, et al.: A His19 to Ala mutant of melanoma growth-stimulating activity is a partial antagonist of the CXCR2 receptor. J Immunol 161:4944–4949, 1998
Hayashi S, Kurdowska A, Miller EJ, et al.: Synthetic hexa-and heptapeptides that inhibit IL-8 from binding to and activating human blood neutrophils. J Immunol 154:814–824, 1995
Miller EJ, Cohen AB, Peterson BT: Peptide inhibitor of interleukin-8 (IL-8) reduces staphylococcal enterotoxin-A (SEA) induced neutrophil trafficking to the lung. Inflamm Res 45:393–397, 1996
Hayashi S, Kurdowska A, Cohen AB, et al.: A synthetic peptide inhibitor for alpha-chemokines inhibits the growth of melanoma cell lines. J Clin Invest 99:2581–2587, 1997
Fujisawa N, Hayashi S, Miller EJ: A synthetic peptide inhibitor for alpha-chemokines inhibits the tumour growth and pulmonary metastasis of human melanoma cells in nude mice [in process citation]. Melanoma Res 9:105–114, 1999
Fujisawa N, Hayashi S, Kurdowska A, et al.: Inhibition of GROalpha-induced human endothelial cell proliferation by the alpha-chemokine inhibitor antileukinate. Cytokine 11:231–238, 1999
Zhang YJ, Rutledge BJ, Rollins BJ: Structure/activity analysis of human monocyte chemoattractant protein-1 (MCP-1) by mutagenesis. Identification of a mutated protein that inhibits MCP-1-mediated monocyte chemotaxis. J Biol Chem 269:15918–15924, 1994
Gong JH, Clark-Lewis I: Antagonists of monocyte chemoattractant protein I identified by modification of functionally critical NH2-terminal residues. J Exp Med 181:631–640, 1995
Gong JH, Ratkay LG, Waterfield JD, et al.: An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-1pr mouse model. J Exp Med 186:131–137, 1997
Gong JH, Uguccioni M, Dewald B, et al.: RANTES and MCP-3 antagonists bind multiple chemokine receptors. J Biol Chem 271:10521–10527, 1996
Murakami T, Nakajima T, Koyanagi Y, et al.: A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 186:1389–1393, 1997
Tamamura H, Imai M, Ishihara T, et al.: Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection. Bioorg Med Chem 6:1033–1041, 1998
Crump MP, Gong JH, Loetscher P, et al.: Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J 16:6996–7007, 1997
Loetscher P, Gong JH, Dewald B, et al.: N-terminal peptides of stromal cell-derived factor-1 with CXC chemokine receptor 4 agonist and antagonist activities. J Biol Chem 273:22279–22283, 1998
Heveker N, Montes M, Germeroth L, et al.: Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides. Curr Biol 8:369–376, 1998
Mack M, Luckow B, Nelson PJ, et al.: Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: A novel inhibitory mechanism of HIV infectivity. J Exp Med 187:1215–1224, 1998
Simmons G, Clapham PR, Picard L, et al.: Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276:276–279, 1997
Proudfoot AE, Power CA, Hoogewerf AJ, et al.: Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 271:2599–2603, 1996
Elsner J, Petering H, Kimmig D, et al.: The CC chemokine receptor antagonist met-RANTES inhibits eosinophil effector functions. Int Arch Allergy Immunol 118:462–465, 1999
Yang OO, Swanberg SL, Lu Z, et al.: Enhanced inhibition of human immunodeficiency virus type 1 by Met-stromal-derived factor 1beta correlates with down-modulation of CXCR4. J Virol 73:4582–4589, 1999
Chen JD, Bai X, Yang AG, et al.: Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy. Nat Med 3:1110–1116, 1997
Yang AG, Bai X, Huang XF, et al.: Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection. Proc Natl Acad Sci USA 94:11567–11572, 1997
White JR, Lee JM, Young PR, et al.: Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 273:10095–10098, 1998
De Clercq E, Yamamoto N, Pauwels R, et al.: Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc Natl Acad Sci USA 89:5286–5290, 1992
Donzella GA, Schols D, Lin SW, et al.: AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 4:72–77, 1998
Schols D, Struyf S, Van Damme J, et al.: Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 186:1383–1388, 1997
Labrosse B, Brelot A, Heveker N, et al.: Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J Virol 72:6381–6388, 1998
de Vreese K, Kofler-Mongold V, Leutgeb C, et al.: The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J Virol 70:689–696, 1996
Schols D, Este JA, Cabrera C, et al.: T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J Virol 72:4032–4037, 1998
Este JA, Cabrera C, Blanco J, et al.: Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4 [in process citation]. J Virol 73:5577–5585, 1999
Ma Q, Jones D, Borghesani PR, et al.: Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4-and SDF-1-deficient mice. Proc Natl Acad Sci USA 95:9448–9453, 1998
Nagasawa T, Hirota S, Tachibana K, et al.: Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382:635–638, 1996
Salcedo R, Wasserman K, Young HA, et al.: Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol 154:1125–1135, 1999
Hesselgesser J, Ng HP, Liang M, et al.: Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor. J Biol Chem 273:15687–15692, 1998
Cooke SP, Forrest G, Venables PJ, et al.: The delta32 deletion of CCR5 receptor in rheumatoid arthritis. Arth Rheum 41:1135–1136, 1998
Altman GB, Altman LC, Luchtel DL, et al.: Release of RANTES from nasal and bronchial epithelial cells. Cell Biol Toxicol 13:205–213, 1997
Garred P, Madsen HO, Petersen J, et al.: CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J Rheumatol 25:1462–1465, 1998
Karpus WJ, Lukacs NW, McRae BL, et al.: An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol 155:5003–5010, 1995
Serody JS, Cook DN, Kirby SL, et al.: Murine T lymphocytes incapable of producing macrophage inhibitory protein-1 are impaired in causing graft-versus-host disease across a class I but not class II major histocompatibility complex barrier. Blood 93:43–50, 1999
Baba M, Nishimura O, Kanzaki N, et al.: A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 96:5698–5703, 1999
Whitby D, Boshoff C: Kaposi's sarcoma herpesvirus as a new paradigm for virus-induced oncogenesis. Curr Opin Oncol 10:405–412, 1998
Verma MJ, Lloyd A, Rager H, et al.: Chemokines in acute anterior uveitis. Curr Eye Res 16:1202–1208, 1997
Terada N, Maesako K, Hamano N, et al.: RANTES production in nasal epithelial cells and endothelial cells. J Allergy Clin Immunol 98:S230–237, 1996
Ciomei M, Pastori W, Mariani M, et al.: New sulfonated distamycin A derivatives with bFGF complexing activity. Biochem Pharmacol 47:295–302, 1994
Sola F, Farao M, Ciomei M, et al.: FCE 27266, a sulfonic distamycin derivative, inhibits experimental and spontaneous lung and liver metastasis. Invasion Metastasis 15:222–231, 1995
Sola F, Farao M, Pesenti E, et al.: Antitumor activity of FCE 26644 a new growth-factor complexing molecule. Cancer Chemother Pharmacol 36:217–222, 1995
Clanton DJ, Buckheit RW Jr, Terpening SJ, et al.: Novel sulfonated and phosphonated analogs of distamycin which inhibit the replication of HIV. Antiviral Res 27:335–354, 1995
Howard OM, Oppenheim JJ, Hollingshead MG, et al.: Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: A candidate for chemotherapeutic and microbicidal application. J Med Chem 41:2184–2193, 1998
Howard OM, Korte T, Tarasova NI, et al.: Small molecule inhibitor of HIV-1 cell fusion blocks chemokine receptor-mediated function. J Leukoc Biol 64:6–13, 1998
Mosier DE, Picchio GR, Gulizia RJ, et al.: Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J Virol 73:3544–3550, 1999
Howard OM, Shirakawa AK, Turpin JA, et al.: Naturally occurring CCR5 extracellular and transmembrane domain variants affect HIV-1 Co-receptor and ligand binding function. J Biol Chem 274:16228–16234, 1999
Manna SK, Samanta S, Samanta AK: Hamycin inhibits IL-8-induced biologic response by modulating its receptor in human polymorphonuclear neutrophils. J Immunol 159:5042–5052, 1997
Thomas AH: Analysis and assay of polyene antifungal antibiotics. A review. Analyst 101:321–340, 1976
Thomas AH: Suggested mechanisms for the antimycotic activity of the polyene antibiotics and the N-substituted imidazoles. J Antimicrob Chemother 17:269–279, 1986
Moonis M, Ahmad I, Bachhawat BK: Liposomal hamycin in the control of experimental aspergillosis in mice: effect of phosphatidic acid with and without cholesterol. J Antimicrob Chemother 31:569–579, 1993
Mehta RT, McQueen TJ, Keyhani A, et al.: Liposomal hamycin: Reduced toxicity and improved antifungal efficacy in vitro and in vivo. J Infect Dis 164:1003–1006, 1991
Sozzani S, Bonecchi R, D'Amico G, et al.: Old and new chemokines. Pharmacological regulation of chemokine production and receptor expression: Mini-review. J Chemother 10:142–145, 1998
Rovai LE, Herschman HR, Smith JB: The murine neutrophil-chemoattractant chemokines LIX, KC, and MIP-2 have distinct induction kinetics, tissue distributions, and tissue-specific sensitivities to glucocorticoid regulation in endotoxemia. J Leukocyte Biol 64:494–502, 1998
Standiford TJ, Kunkel SL, Rolfe MW, et al.: Regulation of human alveolar macrophage-and blood monocyte-derived interleukin-8 by prostaglandin E2 and dexamethasone. Am J Respir Cell Mol Biol 6:75–81, 1992
Kovacs EJ, Faunce DE, Ramer-Quinn DS, et al.: Estrogen regulation of JE/MCP-1 mRNA expression in fibroblasts. J Leukocyte Biol 59:562–568, 1996
Slavin J, Unemori E, Hunt TK, et al.: Monocyte chemotactic protein-1 (MCP-1) mRNA is down-regulated in human dermal fibroblasts by dexamethasone: Differential regulation by TGF-beta. Growth Factors 12:151–157, 1995
Yamada K, Hayashi T, Kuzuya M, et al.: Physiological concentration of 17 beta-estradiol inhibits chemotaxis of human monocytes in response to monocyte chemotactic protein 1. Artery 22:24–35, 1996
Wang P, Wu P, Anthes JC, et al.: Interleukin-10 inhibits interleukin-8 production in human neutrophils. Blood 83:2678–2683, 1994
Tumpey TM, Cheng H, Yan XT, et al.: Chemokine synthesis in the HSV-1-infected cornea and its suppression by interleukin-10. J Leukocyte Biol 63:486–492, 1998
Gerritsma JS, van Kooten C, Gerritsen AF, et al.: Transforming growth factor-beta 1 regulates chemokine and complement production by human proximal tubular epithelial cells. Kidney Int 53:609–616, 1998
Kucharzik T, Lugering N, Pauels HG, et al.: IL-4, IL-10 and IL-13 down-regulate monocyte-chemoattracting protein-1 (MCP-1) production in activated intestinal epithelial cells. Clin Exp Immunol 111:152–157, 1998
John M, Au BT, Jose PJ, et al.: Expression and release of interleukin-8 by human airway smooth muscle cells: Inhibition by Th-2 cytokines and corticosteroids. Am J Respir Cell Mol Biol 18:84–90, 1998
Hedrick JA, Helms A, Vicari A, et al.: Characterization of a novel CC chemokine, HCC-4, whose expression is increased by interleukin-10. Blood 91:4242–4247, 1998
Ohmori Y, Hamilton TA: The interferon-stimulated response element and a kappa B site mediate synergistic inductionof murine IP-10 gene transcription by IFN-gamma and TNF-alpha. J Immunol 154:5235–5244, 1995
Whitson RH Jr., Wong WL, Itakura K: Platelet factor 4 selectively inhibits binding of TGF-beta 1 to the type I TGF-beta 1 receptor. J Cell Biochem 47:31–42, 1991
Szabo C, Scott GS, Virag L, et al.: Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists. Br J Pharmacol 125:379–387, 1998
Verghese MW, Kneisler TB, Boucheron JA: P2U agonists induce chemotaxis and actin polymerization in human neutrophils and differentiated HL60 cells. J Biol Chem 271:15597–15601, 1996
Grimm MC, Ben-Baruch A, Taub DD, et al.: Opiates transdeactivate chemokine receptors: Delta and mu opiate receptor-mediated heterologous desensitization. J Exp Med 188:317–325, 1998
Ali H, Richardson RM, Haribabu B, et al.: Chemoattractant receptor cross-desensitization. J Biol Chem 274:6027–6030, 1999
Au BT, Teixeira MM, Collins PD, et al.: Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: Synergism with prostanoids and salbutamol. Br J Pharmacol 123:1260–1266, 1998
Su SB, Gao J, Gong W, et al.: T21/DP107, a synthetic leucine zipper-like domain of the HIV-1 envelope gp41, attracts and activates human phagocytes by using G-protein-coupled formyl peptide receptors. J Immunol 162:5924–5930, 1999
Su SB, Gong WH, Gao JL, et al.: T20/DP178, an ectodomain peptide of human immunodeficiency virus type 1 gp41, is an activator of human phagocyte N-formyl peptide receptor. Blood 93:3885–3892, 1999
Deng X, Ueda H, Su SB, et al.: A synthetic peptide derived from HIV-1 gp120 down-regulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the seven-transmembrane G protein-coupled receptor FPRL-1/LXAR. Blood 94:1165–1173, 1999
Su SB, Gong W, Gao JL, et al.: A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med 189:395–402, 1999
Badolato R, Johnston JA, Wang JM, et al.: Serum amyloid A induces calcium mobilization and chemotaxis of human monocytes by activating a pertussis toxin-sensitive signaling pathway. J Immunol 155:4004–4010, 1995
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Howard, O.M.Z., Oppenheim, J.J. & Wang, J.M. Chemokines as Molecular Targets for Therapeutic Intervention. J Clin Immunol 19, 280–292 (1999). https://doi.org/10.1023/A:1020587407535
Issue Date:
DOI: https://doi.org/10.1023/A:1020587407535